vs
GE医疗（CCRN）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
GE医疗的季度营收约是REPLIGEN CORP的1.2倍（$236.8M vs $197.9M），REPLIGEN CORP净利率更高（6.7% vs -35.0%，领先41.7%），REPLIGEN CORP同比增速更快（13.6% vs -23.6%），REPLIGEN CORP自由现金流更多（$17.6M vs $16.1M），过去两年REPLIGEN CORP的营收复合增速更高（14.4% vs -21.0%）
GE医疗是总部位于美国伊利诺伊州芝加哥的医疗科技企业，品牌标识为GE HealthCare。公司主要业务分为四大板块：包含分子影像、CT、磁共振、妇科筛查及X光设备的医学影像业务、超声业务，以及聚焦远程患者监测、麻醉呼吸护理、心脏诊断、婴幼儿护理的患者护理解决方案业务，此外还开展医药相关业务。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
CCRN vs RGEN — 直观对比
营收规模更大
CCRN
是对方的1.2倍
$197.9M
营收增速更快
RGEN
高出37.3%
-23.6%
净利率更高
RGEN
高出41.7%
-35.0%
自由现金流更多
RGEN
多$1.4M
$16.1M
两年增速更快
RGEN
近两年复合增速
-21.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $236.8M | $197.9M |
| 净利润 | $-82.9M | $13.3M |
| 毛利率 | — | 52.5% |
| 营业利润率 | -30.2% | 9.0% |
| 净利率 | -35.0% | 6.7% |
| 营收同比 | -23.6% | 13.6% |
| 净利润同比 | -2109.7% | 143.9% |
| 每股收益（稀释后） | $-2.56 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CCRNRGEN
| Q4 25 | $236.8M | $197.9M | ||
| Q3 25 | $250.1M | $188.8M | ||
| Q2 25 | $274.1M | $182.4M | ||
| Q1 25 | $293.4M | $169.2M | ||
| Q4 24 | $309.9M | $174.1M | ||
| Q3 24 | $315.1M | $154.9M | ||
| Q2 24 | $339.8M | $154.1M | ||
| Q1 24 | $379.2M | $151.3M |
净利润CCRNRGEN
| Q4 25 | $-82.9M | $13.3M | ||
| Q3 25 | $-4.8M | $14.9M | ||
| Q2 25 | $-6.7M | $14.9M | ||
| Q1 25 | $-490.0K | $5.8M | ||
| Q4 24 | $-3.8M | $-30.3M | ||
| Q3 24 | $2.6M | $-654.0K | ||
| Q2 24 | $-16.1M | $3.3M | ||
| Q1 24 | $2.7M | $2.1M |
毛利率CCRNRGEN
| Q4 25 | — | 52.5% | ||
| Q3 25 | 20.4% | 53.2% | ||
| Q2 25 | 20.4% | 50.0% | ||
| Q1 25 | 20.0% | 53.6% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | 20.4% | 50.0% | ||
| Q2 24 | 20.8% | 49.8% | ||
| Q1 24 | 20.4% | 49.5% |
营业利润率CCRNRGEN
| Q4 25 | -30.2% | 9.0% | ||
| Q3 25 | -2.4% | 8.9% | ||
| Q2 25 | -2.1% | 7.6% | ||
| Q1 25 | -0.3% | 3.9% | ||
| Q4 24 | -1.1% | -17.7% | ||
| Q3 24 | 0.9% | -5.1% | ||
| Q2 24 | -5.7% | 1.0% | ||
| Q1 24 | 0.8% | 1.3% |
净利率CCRNRGEN
| Q4 25 | -35.0% | 6.7% | ||
| Q3 25 | -1.9% | 7.9% | ||
| Q2 25 | -2.4% | 8.2% | ||
| Q1 25 | -0.2% | 3.4% | ||
| Q4 24 | -1.2% | -17.4% | ||
| Q3 24 | 0.8% | -0.4% | ||
| Q2 24 | -4.7% | 2.2% | ||
| Q1 24 | 0.7% | 1.4% |
每股收益（稀释后）CCRNRGEN
| Q4 25 | $-2.56 | $0.24 | ||
| Q3 25 | $-0.15 | $0.26 | ||
| Q2 25 | $-0.20 | $0.26 | ||
| Q1 25 | $-0.02 | $0.10 | ||
| Q4 24 | $-0.13 | $-0.55 | ||
| Q3 24 | $0.08 | $-0.01 | ||
| Q2 24 | $-0.47 | $0.06 | ||
| Q1 24 | $0.08 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $108.7M | $767.6M |
| 总债务越低越好 | — | $542.2M |
| 股东权益账面价值 | $322.8M | $2.1B |
| 总资产 | $449.0M | $2.9B |
| 负债/权益比越低杠杆越低 | — | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资CCRNRGEN
| Q4 25 | $108.7M | $767.6M | ||
| Q3 25 | $99.1M | $748.7M | ||
| Q2 25 | $81.2M | $708.9M | ||
| Q1 25 | $80.7M | $697.2M | ||
| Q4 24 | $81.6M | $757.4M | ||
| Q3 24 | $64.0M | $784.0M | ||
| Q2 24 | $69.6M | $809.1M | ||
| Q1 24 | $5.2M | $780.6M |
总债务CCRNRGEN
| Q4 25 | — | $542.2M | ||
| Q3 25 | — | $537.9M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $525.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益CCRNRGEN
| Q4 25 | $322.8M | $2.1B | ||
| Q3 25 | $408.1M | $2.1B | ||
| Q2 25 | $412.2M | $2.1B | ||
| Q1 25 | $418.2M | $2.0B | ||
| Q4 24 | $419.0M | $2.0B | ||
| Q3 24 | $424.7M | $2.0B | ||
| Q2 24 | $433.3M | $2.0B | ||
| Q1 24 | $462.4M | $2.0B |
总资产CCRNRGEN
| Q4 25 | $449.0M | $2.9B | ||
| Q3 25 | $538.2M | $2.9B | ||
| Q2 25 | $553.8M | $2.9B | ||
| Q1 25 | $576.2M | $2.9B | ||
| Q4 24 | $589.3M | $2.8B | ||
| Q3 24 | $597.4M | $2.8B | ||
| Q2 24 | $602.9M | $2.9B | ||
| Q1 24 | $648.4M | $2.8B |
负债/权益比CCRNRGEN
| Q4 25 | — | 0.26× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.27× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $18.2M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | $16.1M | $17.6M |
| 自由现金流率自由现金流/营收 | 6.8% | 8.9% |
| 资本支出强度资本支出/营收 | 0.9% | 4.1% |
| 现金转化率经营现金流/净利润 | — | 1.93× |
| 过去12个月自由现金流最近4个季度 | $40.1M | $93.9M |
8季度趋势，按日历期对齐
经营现金流CCRNRGEN
| Q4 25 | $18.2M | $25.7M | ||
| Q3 25 | $20.1M | $48.1M | ||
| Q2 25 | $4.2M | $28.6M | ||
| Q1 25 | $5.7M | $15.0M | ||
| Q4 24 | $24.2M | $39.2M | ||
| Q3 24 | $7.5M | $49.3M | ||
| Q2 24 | $82.4M | $42.2M | ||
| Q1 24 | $6.0M | $44.7M |
自由现金流CCRNRGEN
| Q4 25 | $16.1M | $17.6M | ||
| Q3 25 | $17.9M | $43.4M | ||
| Q2 25 | $2.3M | $21.5M | ||
| Q1 25 | $3.8M | $11.4M | ||
| Q4 24 | $21.7M | $33.6M | ||
| Q3 24 | $6.3M | $42.3M | ||
| Q2 24 | $79.6M | $37.4M | ||
| Q1 24 | $3.8M | $36.4M |
自由现金流率CCRNRGEN
| Q4 25 | 6.8% | 8.9% | ||
| Q3 25 | 7.2% | 23.0% | ||
| Q2 25 | 0.8% | 11.8% | ||
| Q1 25 | 1.3% | 6.8% | ||
| Q4 24 | 7.0% | 19.3% | ||
| Q3 24 | 2.0% | 27.3% | ||
| Q2 24 | 23.4% | 24.3% | ||
| Q1 24 | 1.0% | 24.0% |
资本支出强度CCRNRGEN
| Q4 25 | 0.9% | 4.1% | ||
| Q3 25 | 0.9% | 2.5% | ||
| Q2 25 | 0.7% | 3.9% | ||
| Q1 25 | 0.6% | 2.1% | ||
| Q4 24 | 0.8% | 3.2% | ||
| Q3 24 | 0.4% | 4.5% | ||
| Q2 24 | 0.8% | 3.1% | ||
| Q1 24 | 0.6% | 5.5% |
现金转化率CCRNRGEN
| Q4 25 | — | 1.93× | ||
| Q3 25 | — | 3.23× | ||
| Q2 25 | — | 1.92× | ||
| Q1 25 | — | 2.57× | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.92× | — | ||
| Q2 24 | — | 12.70× | ||
| Q1 24 | 2.23× | 21.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CCRN
| Temporary Staffing Services | $189.6M | 80% |
| Physician Staffing | $42.5M | 18% |
| Other Services | $4.7M | 2% |
RGEN
暂无分部数据
